Reversal of obesity-induced hypertriglyceridemia by (R)-α-lipoic acid in ZDF (fa/fa) rats

Biochemical and Biophysical Research Communications

Volumn 439, Issue 3, 2013, Pages 390-395

  Yi, Xiaohua ^a   Pashaj, Anjeza ^a   Xia, Mengna ^a   Moreau, Régis ^a  

^a UNIVERSITY OF NEBRASKA LINCOLN   (United States)

Author keywords

Dyslipidemia; Lipotoxicity; Steatosis; Triglyceride; Zucker rat

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ADENOSINE TRIPHOSPHATE; ADIPONUTRIN; CARNITINE PALMITOYLTRANSFERASE 1 ALPHA; CARNITINE PALMITOYLTRANSFERASE 1 BETA; CARNITINE PALMITOYLTRANSFERASE I; CITRATE SYNTHASE; FATTY ACID; FATTY ACID SYNTHASE; FIBROBLAST GROWTH FACTOR 21; GLYCEROL 3 PHOSPHATE ACYLTRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; KETONE BODY; LIVER PROTEIN; PALMITOYL COENZYME A HYDROLASE; PALMITOYL COENZYME A HYDROLASE 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROTEIN; THIOCTIC ACID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ABDOMINAL FAT; ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; ENZYME ACTIVE SITE; EPIDIDYMIS FAT; FATTY ACID BLOOD LEVEL; FATTY ACID METABOLISM; GENE REPRESSION; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; LIPID METABOLISM; LIVER METABOLISM; MALE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSAL REACTION; SKELETAL MUSCLE; TRIACYLGLYCEROL BLOOD LEVEL; ZUCKER DIABETIC FATTY RAT;

DYSLIPIDEMIA; LIPOTOXICITY; STEATOSIS; TRIGLYCERIDE; ZUCKER RAT;

ANIMALS; BODY WEIGHT; FATTY ACIDS; GENE EXPRESSION REGULATION; HYPERTRIGLYCERIDEMIA; INSULIN; KETONE BODIES; MALE; OBESITY; RATS; RATS, ZUCKER; THIOCTIC ACID; TRIGLYCERIDES;

RATTUS;

EID: 84884588027     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.08.063     Document Type: Article

References (40)

1. NCEP, Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III), Jama 285 (2001) 2486-2497.
2. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287:356-359.
3. Rubins H.B., Robins S.J., Collins D., Fye C.L., Anderson J.W., Elam M.B., Faas F.H., Linares E., Schaefer E.J., Schectman G., Wilt T.J., Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med. 1999, 341:410-418.
4. Vakkilainen J., Steiner G., Ansquer J.C., Aubin F., Rattier S., Foucher C., Hamsten A., Taskinen M.R. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the diabetes atherosclerosis intervention study. Circulation 2003, 107:1733-1737.
5. Ginsberg H.N., Elam M.B., Lovato L.C., Crouse J.R., Leiter L.A., Linz P., Friedewald W.T., Buse J.B., Gerstein H.C., Probstfield J., Grimm R.H., Ismail-Beigi F., Bigger J.T., Goff D.C., Cushman W.C., Simons-Morton D.G., Byington R.P. Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med. 2010, 362:1563-1574.
6. Ting R.D., Keech A.C., Drury P.L., Donoghoe M.W., Hedley J., Jenkins A.J., Davis T.M., Lehto S., Celermajer D., Simes R.J., Rajamani K., Stanton K. Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD study. Diabetes Care 2012, 35:218-225.
7. Ferdinand K.C., Davidson M.H., Kelly M.T., Setze C.M. One-year efficacy and safety of rosuvastatin+fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response. Am. J. Cardiovasc. Drugs : Drugs, Devices, and other Interventions 2012, 12:117-125.
8. Alsheikh-Ali A.A., Kuvin J.T., Karas R.H. Risk of adverse events with fibrates. Am. J. Cardiol. 2004, 94:935-938.
9. Oh R.C., Lanier J.B. Management of hypertriglyceridemia. Am. Fam. Physician 2007, 75:1365-1371.
10. Bortolini M., Wright M.B., Bopst M., Balas B. Examining the safety of PPAR agonists - current trends and future prospects. Expert Opin. Drug Safety 2013, 12:65-79.
11. Shay K.P., Moreau R.F., Smith E.J., Smith A.R., Hagen T.M. Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochim. Biophys. Acta 2009, 1790:1149-1160.
12. Kim M.S., Park J.Y., Namkoong C., Jang P.G., Ryu J.W., Song H.S., Yun J.Y., Namgoong I.S., Ha J., Park I.S., Lee I.K., Viollet B., Youn J.H., Lee H.K., Lee K.U. Anti-obesity effects of alpha-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinase. Nat. Med. 2004, 10:727-733.
13. Zhang W.J., Bird K.E., McMillen T.S., LeBoeuf R.C., Hagen T.M., Frei B. Dietary alpha-lipoic acid supplementation inhibits atherosclerotic lesion development in apolipoprotein E-deficient and apolipoprotein E/low-density lipoprotein receptor-deficient mice. Circulation 2008, 117:421-428.
14. Butler J.A., Hagen T.M., Moreau R. Lipoic acid improves hypertriglyceridemia by stimulating triacylglycerol clearance and downregulating liver triacylglycerol secretion. Arch. Biochem. Biophys. 2009, 485:63-71.
15. Castro M.C., Massa M.L., Schinella G., Gagliardino J.J., Francini F. Lipoic acid prevents liver metabolic changes induced by administration of a fructose-rich diet. Biochim. Biophys. Acta 1830, 2013:2226-2232.
16. R.G. Alken, D. Koegst, G. Fries, Treatment of lipid metabolic disorders using 5-(1,2-dithiolan-3-yl)valeric acid (alpha-lipoic acid) or its physiologically compatible salts, US Patent # 6,518,300 B2 (2003).
17. Zhang Y., Han P., Wu N., He B., Lu Y., Li S., Liu Y., Zhao S., Liu L., Li Y. Amelioration of lipid abnormalities by alpha-lipoic acid through antioxidative and anti-inflammatory effects. Obesity 2011, 19:1647-1653.
18. Donnelly K.L., Smith C.I., Schwarzenberg S.J., Jessurun J., Boldt M.D., Parks E.J. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 2005, 115:1343-1351.
19. Roncero C., Goodridge A.G. Hexanoate and octanoate inhibit transcription of the malic enzyme and fatty acid synthase genes in chick embryo hepatocytes in culture. J. Biol. Chem. 1992, 267:14918-14927.
20. Hillgartner F.B., Charron T. Arachidonate and medium-chain fatty acids inhibit transcription of the acetyl-CoA carboxylase gene in hepatocytes in culture. J. Lipid Res. 1997, 38:2548-2557.
21. Dongol B., Shah Y., Kim I., Gonzalez F.J., Hunt M.C. The acyl-CoA thioesterase I is regulated by PPARalpha and HNF4alpha via a distal response element in the promoter. J. Lipid Res. 2007, 48:1781-1791.
22. Wolfrum C., Borrmann C.M., Borchers T., Spener F. Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors alpha - and gamma-mediated gene expression via liver fatty acid binding protein: a signaling path to the nucleus. Proc. Nat. Acad. Sci. U.S.A. 2001, 98:2323-2328.
23. Turner N., Bruce C.R., Beale S.M., Hoehn K.L., So T., Rolph M.S., Cooney G.J. Excess lipid availability increases mitochondrial fatty acid oxidative capacity in muscle: evidence against a role for reduced fatty acid oxidation in lipid-induced insulin resistance in rodents. Diabetes 2007, 56:2085-2092.
24. Zhang L., Keung W., Samokhvalov V., Wang W., Lopaschuk G.D. Role of fatty acid uptake and fatty acid beta-oxidation in mediating insulin resistance in heart and skeletal muscle. Biochim. Biophys. Acta 1801, 2010:1-22.
25. Koves T.R., Ussher J.R., Noland R.C., Slentz D., Mosedale M., Ilkayeva O., Bain J., Stevens R., Dyck J.R., Newgard C.B., Lopaschuk G.D., Muoio D.M. Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab. 2008, 7:45-56.
26. Lee W.J., Song K.H., Koh E.H., Won J.C., Kim H.S., Park H.S., Kim M.S., Kim S.W., Lee K.U., Park J.Y. Alpha-lipoic acid increases insulin sensitivity by activating AMPK in skeletal muscle. Biochem. Biophys. Res. Commun. 2005, 332:885-891.
27. Lee W.J., Kim M., Park H.S., Kim H.S., Jeon M.J., Oh K.S., Koh E.H., Won J.C., Kim M.S., Oh G.T., Yoon M., Lee K.U., Park J.Y. AMPK activation increases fatty acid oxidation in skeletal muscle by activating PPARalpha and PGC-1. Biochem. Biophys. Res. Commun. 2006, 340:291-295.
28. Timmers S., de Vogel-van den Bosch J., Towler M.C., Schaart G., Moonen-Kornips E., Mensink R.P., Hesselink M.K., Hardie D.G., Schrauwen P. Prevention of high-fat diet-induced muscular lipid accumulation in rats by alpha lipoic acid is not mediated by AMPK activation. J. Lipid Res. 2010, 51:352-359.
29. Yu X., McCorkle S., Wang M., Lee Y., Li J., Saha A.K., Unger R.H., Ruderman N.B. Leptinomimetic effects of the AMP kinase activator AICAR in leptin-resistant rats: prevention of diabetes and ectopic lipid deposition. Diabetologia 2004, 47:2012-2021.
30. Minokoshi Y., Kim Y.B., Peroni O.D., Fryer L.G., Muller C., Carling D., Kahn B.B. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002, 415:339-343.
31. Steinberg G.R., Rush J.W., Dyck D.J. AMPK expression and phosphorylation are increased in rodent muscle after chronic leptin treatment. Am. J. Physiol. Endocrinol. Metab. 2003, 284:E648-E654.
32. Kharitonenkov A., Shiyanova T.L., Koester A., Ford A.M., Micanovic R., Galbreath E.J., Sandusky G.E., Hammond L.J., Moyers J.S., Owens R.A., Gromada J., Brozinick J.T., Hawkins E.D., Wroblewski V.J., Li D.S., Mehrbod F., Jaskunas S.R., Shanafelt A.B. FGF-21 as a novel metabolic regulator. J. Clin. Invest. 2005, 115:1627-1635.
33. Coskun T., Bina H.A., Schneider M.A., Dunbar J.D., Hu C.C., Chen Y., Moller D.E., Kharitonenkov A. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 2008, 149:6018-6027.
34. Xu J., Lloyd D.J., Hale C., Stanislaus S., Chen M., Sivits G., Vonderfecht S., Hecht R., Li Y.S., Lindberg R.A., Chen J.L., Jung D.Y., Zhang Z., Ko H.J., Kim J.K., Veniant M.M. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009, 58:250-259.
35. Berglund E.D., Li C.Y., Bina H.A., Lynes S.E., Michael M.D., Shanafelt A.B., Kharitonenkov A., Wasserman D.H. Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. Endocrinology 2009, 150:4084-4093.
36. Yadav V., Marracci G., Lovera J., Woodward W., Bogardus K., Marquardt W., Shinto L., Morris C., Bourdette D. Lipoic acid in multiple sclerosis: a pilot study. Mult. Scler. 2005, 11:159-165.
37. Ziegler D., Ametov A., Barinov A., Dyck P.J., Gurieva I., Low P.A., Munzel U., Yakhno N., Raz I., Novosadova M., Maus J., Samigullin R. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care 2006, 29:2365-2370.
38. Li H., Gao Z., Zhang J., Ye X., Xu A., Ye J., Jia W. Sodium Butyrate Stimulates Expression of Fibroblast Growth Factor 21 in Liver by Inhibition of Histone Deacetylase 3. Diabetes 2012, 61:797-806.
39. Badman M.K., Pissios P., Kennedy A.R., Koukos G., Flier J.S., Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 2007, 5:426-437.
40. Finlay L.A., Michels A.J., Butler J.A., Smith E.J., Monette J.S., Moreau R.F., Petersen S.K., Frei B., Hagen T.M. R-alpha-lipoic acid does not reverse hepatic inflammation of aging, but lowers lipid anabolism, while accentuating circadian rhythm transcript profiles, American journal of physiology. Regul. Integr. Comp. Physiol. 2012, 302:R587-R597.